Drug Interactions between avanafil and eplerenone
This report displays the potential drug interactions for the following 2 drugs:
- avanafil
- eplerenone
Interactions between your drugs
eplerenone avanafil
Applies to: eplerenone and avanafil
MONITOR: Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications or medications with hypotensive properties, including vasodilators. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation and thus blood pressure (BP) reduction. For example, when sildenafil (100 mg) was coadministered with amlodipine (5 mg or 10 mg) to hypertensive patients, the mean additional reduction in supine BP was 8/7 mmHg. Likewise, in a group of patients whose hypertension was controlled with nifedipine slow-release (30 mg or 60 mg) once daily, the addition of vardenafil (20 mg) produced a mean additional supine BP reduction of 6/5 mmHg compared to placebo. When coadministered with amlodipine (5 mg) daily or enalapril (20 mg) daily, a single dose of avanafil (200 mg) produced a mean maximum decrease in supine systolic BP of 1.2 mmHg (amlodipine) and supine BP of 1.8/3.5 mmHg (enalapril) compared to placebo.
MANAGEMENT: Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents or agents with hypotensive properties. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.
References (3)
- (2001) "Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals
- (2003) "Product Information. Levitra (vardenafil)." Bayer
- (2012) "Product Information. Stendra (avanafil)." Vivus LLC.
Drug and food interactions
eplerenone food
Applies to: eplerenone
GENERALLY AVOID: Coadministration with grapefruit juice may increase the plasma concentrations of eplerenone. The primary mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. Inhibition of hepatic CYP450 3A4 may also contribute. In drug interaction studies, administration of a single 100 mg dose of eplerenone in combination with grapefruit juice resulted in a 25% increase in eplerenone systemic exposure (AUC). High blood levels of eplerenone can increase the risk of side effects including hyperkalemia. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.
MANAGEMENT: It may be advisable for patients to avoid the consumption of grapefruit, grapefruit juice, or supplements that contain grapefruit during treatment with eplerenone.
References (3)
- (2002) "Product Information. Inspra (eplerenone)." Searle
- (2021) "Product Information. Eplerenone (eplerenone)." MSN Laboratories Europe Ltd
- (2023) "Product Information. Eplerenone (Apotex) (eplerenone)." Apotex Pty Ltd
avanafil food
Applies to: avanafil
GENERALLY AVOID: Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors are used with alcohol, as both are mild systemic vasodilators. In clinical pharmacology studies, more subjects administered alcohol at a dose of 0.7 g/kg (equivalent to approximately 6 ounces of 80-proof vodka in an 80-kg male; consumed within 10 minutes in study subjects, providing blood alcohol levels of 0.08%) in combination with tadalafil 10 or 20 mg single doses had clinically significant decreases in blood pressure than with alcohol alone. There were reports of postural dizziness, and orthostatic hypotension was observed in some. When tadalafil 20 mg was administered with alcohol at a lower dose of 0.6 g/kg (equivalent to approximately 4 ounces of 80-proof vodka in an 80-kg male), orthostatic hypotension was not observed, dizziness occurred with similar frequency relative to alcohol alone, and the hypotensive effects of alcohol were not potentiated. Neither tadalafil nor alcohol affected the plasma concentrations of the other. Administration of avanafil 200 mg with alcohol at a dose of 0.5 g/kg (equivalent to approximately 3 ounces of 80-proof vodka in a 70-kg male; consumed within 15 minutes in study subjects, providing blood alcohol levels of 0.057%) resulted in additional maximum supine systolic/diastolic blood pressure decreases of 3.5/4.5 mm Hg and additional maximum pulse rate increase of 9.3 bpm compared to alcohol alone, but did not cause orthostatic hypotension or dizziness. The plasma concentrations of alcohol were not affected. Sildenafil 50 mg and vardenafil 20 mg reportedly did not potentiate the hypotensive effect of alcohol in healthy volunteers with mean maximum blood alcohol levels of 0.08% and in healthy volunteers administered alcohol at a dose of 0.5 g/kg, respectively. Alcohol and vardenafil plasma levels were not altered when dosed simultaneously.
GENERALLY AVOID: Coadministration with grapefruit juice is likely to increase the plasma concentrations of avanafil, which is primarily metabolized by CYP450 3A4. However, the interaction has not been studied. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.
MANAGEMENT: Patients taking avanafil should avoid consuming large amounts of alcohol, which may increase the potential for orthostatic signs and symptoms including increase in heart rate, decrease in standing blood pressure, dizziness, and headache. It may also be appropriate to avoid consuming large amounts of grapefruit juice. Some authorities advise that grapefruit juice should be avoided within 24 hours prior to taking avanafil.
References (5)
- (2001) "Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals
- (2003) "Product Information. Levitra (vardenafil)." Bayer
- (2003) "Product Information. Cialis (tadalafil)." Lilly, Eli and Company
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- (2012) "Product Information. Stendra (avanafil)." Vivus LLC.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.